Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.66 |
| ▸ | CCND1 | P24385 | 20/20 | 0.66 |
| ▸ | CDK2 | P24941 | 6/20 | 0.66 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.65 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.56 |
| ▸ | STK16 | O75716 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | ERCC2 | P18074 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | CCND3 | P30281 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087398 | 0.95 | CDK4 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL10087404 | 0.94 | CDK4 (0.67) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL10087330 | 0.93 | CDK4 (0.66) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL10087399 | 0.90 | CDK4 (0.64) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL1115749 | 0.89 | CDK4 (0.70) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL10087329 | 0.89 | CDK4 (0.70) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL12856535 | 0.88 | CDK4 (0.73) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL10087396 | 0.87 | CDK4 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL1179687 | 0.86 | CDK4 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL12856544 | 0.86 | CDK4 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097619-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097619-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2298291-A2 | Kinase inhibitors for treating cancers | Agennix USA Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298292-A2 | Kinase inhibitors for treating cancers | Agennix USA Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100004207-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH INC. | 2010-01-07 | — | — | US | disclosed |
| US-20100004207-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH INC. | 2010-01-07 | — | — | US | disclosed |
| US-7605175-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH AG (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7605175-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH AG (DE) | 2009-10-20 | — | — | US | disclosed |
| US-20090209530-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC BIOTECH, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209530-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC BIOTECH, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| EP-2027853-A2 | Kinase inhibitors for treating cancers | GPC Biotech Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080146555-A1 | Uses of Kinase Inhibitors and Compositions Thereof | GPC BIOTECH, INC (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146555-A1 | Uses of Kinase Inhibitors and Compositions Thereof | GPC BIOTECH, INC (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004207-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | CDK4 14/4885CCND1 55/4885CDK2 4/4885 |
| US-20090209530-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | CDK1, CCNO, CCNI | CDK4 14/4885CCND1 55/4885CDK2 4/4885 |
| US-20080146555-A1 | Uses of Kinase Inhibitors and Compositions Thereof | CCNK, CDK3, CDK6 | CDK4 15/4885CCND1 220/4885CDK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.